Entzündliche Myopathien: Differenzialdiagnose aus histologischer Sicht

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Prof. Elisabeth Jane Rushing

Universitätsspital Zürich, Institut für Neuropathologie, Zürich


AutorIn: cand. med. Marc Emmenegger

Universitätsspital Zürich, Institut für Neuropathologie, Zürich


Referenzen:
1 Dalakas MC, Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325(21):1487–98
2 Dalakas MC, Review: An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011; 37(3):226–42
3 Dalakas MC, Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr Treat Options Neurol 2011; 13(3):311–23
4 Dalakas MC, Pathophysiology of inflammatory and autoimmune myopathies. Presse Med 2011; 40(4 Pt 2):e237–47
5 Dimachkie MM, Idiopathic inflammatory myopathies. J Neuroimmunol 2011; 231(1–2):32–42
6 Mammen AL, Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 2011; 7(6):343–54
7 Yazici Y, Kagen LJ, Clinical presentation of the idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002; 28(4):823–32
8 Dimachkie MM, Barohn RJ, Amato AA, Idiopathic inflammatory myopathies. Neurol Clin 2014; 32(3):595–628, vii
9 Amato AA, Greenberg SA, Inflammatory myopathies. Continuum (Minneap Minn) 2013; 19(6 Muscle Disease):1615–33
10 Choy EH Isenberg DA, Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 2002; 41(1):7–13
11 Luo YB, Mastaglia FL, Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta 2014 [Epub ahead of print]
12 Miller FW, New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis 2012; 71(Suppl 2):i82–5
13 Tournadre A, Dubost JJ, Soubrier M, Treatment of inflammatory muscle disease in adults. Joint Bone Spine 2010; 77(5):390–4
14 Dalakas MC, Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta 2014 [Epub ahead of print]
15 Mastaglia FL, Phillips BA, Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 2002; 28(4):723–41
16 Hoon Lim H et al., A26: Longitudinal disease trajectory of juvenile dermatomyositis. Arthritis Rheumatol 2014; 66(S11):S41–S41
17 Amato AA, Barohn RJ, Idiopathic inflammatory myopathies. Neurol Clin 1997; 15(3):615–48
18 Tansley SL et al., Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) 2014 [Epub ahead of print]
19 Kuo CF et al., Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 2011; 165(6):1273–9
20 Meyer A et al., Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford), 2014 [Epub ahead of print]
21 Prieto S, Grau JM, The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010; 9(5):A330–4
22 Bornemann A, Heitmann S, Lindner A, [Myositides]. Pathologe 2009; 30(5):352–6
23 Dubourg O et al., Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis. Acta Myol 2011; 30(2):103–8
24 Dalakas MC, Sporadic inclusion body myositis–diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006; 2(8):437–47
25 Milisenda JC, Selva-O’Callaghan A, Grau JM, The diagnosis and classification of polymyositis. J Autoimmun 2014; 48–49:118–21

FdR 04|2014

Publikationsdatum: 2014-12-23